ECSP24032906A - Compuestos y métodos dirigidos a la interleucina-34 - Google Patents
Compuestos y métodos dirigidos a la interleucina-34Info
- Publication number
- ECSP24032906A ECSP24032906A ECSENADI202432906A ECDI202432906A ECSP24032906A EC SP24032906 A ECSP24032906 A EC SP24032906A EC SENADI202432906 A ECSENADI202432906 A EC SENADI202432906A EC DI202432906 A ECDI202432906 A EC DI202432906A EC SP24032906 A ECSP24032906 A EC SP24032906A
- Authority
- EC
- Ecuador
- Prior art keywords
- methods
- targetting
- interleukin
- compounds
- antibodies
- Prior art date
Links
- 102100033499 Interleukin-34 Human genes 0.000 title abstract 2
- 101710181549 Interleukin-34 Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273216P | 2021-10-29 | 2021-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP24032906A true ECSP24032906A (es) | 2024-05-31 |
Family
ID=84367272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202432906A ECSP24032906A (es) | 2021-10-29 | 2024-04-29 | Compuestos y métodos dirigidos a la interleucina-34 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11976114B2 (enExample) |
| EP (1) | EP4423127A1 (enExample) |
| JP (3) | JP7622019B2 (enExample) |
| KR (1) | KR20240099349A (enExample) |
| CN (1) | CN118475610A (enExample) |
| AR (1) | AR127484A1 (enExample) |
| AU (1) | AU2022376940A1 (enExample) |
| CA (1) | CA3236555A1 (enExample) |
| CL (1) | CL2024001303A1 (enExample) |
| CO (1) | CO2024005417A2 (enExample) |
| CR (1) | CR20240170A (enExample) |
| DO (1) | DOP2024000076A (enExample) |
| EC (1) | ECSP24032906A (enExample) |
| IL (1) | IL312380A (enExample) |
| MX (1) | MX2024005153A (enExample) |
| PE (1) | PE20241471A1 (enExample) |
| TW (1) | TW202336034A (enExample) |
| WO (1) | WO2023076995A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4472679A1 (en) * | 2022-02-03 | 2024-12-11 | Eli Lilly and Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5828762B2 (ja) | 2008-07-21 | 2015-12-09 | プロビオドルグ エージー | 診断用抗体アッセイ |
| EP2576617B1 (en) | 2010-06-04 | 2016-04-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| LT3042917T (lt) | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| BR112014018961A8 (pt) | 2012-02-06 | 2017-07-11 | Genentech Inc | Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado |
| KR20170031245A (ko) | 2014-07-28 | 2017-03-20 | 노그라 파마 리미티드 | 염증성 장 질환을 진단 및 치료하기 위한 방법 및 조성물 |
| WO2016097420A1 (en) | 2014-12-19 | 2016-06-23 | Universite De Nantes | Anti il-34 antibodies |
| ES3012402T3 (en) * | 2015-04-13 | 2025-04-09 | Pfizer | Therapeutic antibodies and their uses |
| EP3302552A1 (en) | 2015-06-02 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10988529B2 (en) * | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| EP3758736B1 (en) | 2018-03-02 | 2024-05-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Il-34 for use in a method of treating retinal inflammation and neurodegeneration |
| EA202192888A1 (ru) | 2019-05-31 | 2022-03-23 | Эли Лилли Энд Компани | Соединения и способы нацеливания на тау человека |
| AR121898A1 (es) * | 2020-04-30 | 2022-07-20 | Lilly Co Eli | Compuestos y métodos dirigidos a interleucina-34 |
-
2022
- 2022-10-27 TW TW111140796A patent/TW202336034A/zh unknown
- 2022-10-27 KR KR1020247017337A patent/KR20240099349A/ko active Pending
- 2022-10-27 AU AU2022376940A patent/AU2022376940A1/en active Pending
- 2022-10-27 IL IL312380A patent/IL312380A/en unknown
- 2022-10-27 WO PCT/US2022/078776 patent/WO2023076995A1/en not_active Ceased
- 2022-10-27 US US18/050,227 patent/US11976114B2/en active Active
- 2022-10-27 EP EP22814582.7A patent/EP4423127A1/en active Pending
- 2022-10-27 CN CN202280086946.7A patent/CN118475610A/zh active Pending
- 2022-10-27 PE PE2024000938A patent/PE20241471A1/es unknown
- 2022-10-27 JP JP2022172479A patent/JP7622019B2/ja active Active
- 2022-10-27 CA CA3236555A patent/CA3236555A1/en active Pending
- 2022-10-27 MX MX2024005153A patent/MX2024005153A/es unknown
- 2022-10-27 CR CR20240170A patent/CR20240170A/es unknown
- 2022-10-27 AR ARP220102931A patent/AR127484A1/es unknown
-
2024
- 2024-04-05 US US18/628,082 patent/US20240309082A1/en active Pending
- 2024-04-17 JP JP2024066552A patent/JP2024091777A/ja active Pending
- 2024-04-26 CL CL2024001303A patent/CL2024001303A1/es unknown
- 2024-04-26 DO DO2024000076A patent/DOP2024000076A/es unknown
- 2024-04-26 CO CONC2024/0005417A patent/CO2024005417A2/es unknown
- 2024-04-29 EC ECSENADI202432906A patent/ECSP24032906A/es unknown
-
2025
- 2025-01-15 JP JP2025005276A patent/JP2025063187A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023076995A1 (en) | 2023-05-04 |
| JP2023067832A (ja) | 2023-05-16 |
| CR20240170A (es) | 2024-05-24 |
| PE20241471A1 (es) | 2024-07-17 |
| US11976114B2 (en) | 2024-05-07 |
| CO2024005417A2 (es) | 2024-05-30 |
| KR20240099349A (ko) | 2024-06-28 |
| CL2024001303A1 (es) | 2024-08-30 |
| US20240309082A1 (en) | 2024-09-19 |
| AR127484A1 (es) | 2024-01-31 |
| JP2024091777A (ja) | 2024-07-05 |
| CN118475610A (zh) | 2024-08-09 |
| TW202336034A (zh) | 2023-09-16 |
| MX2024005153A (es) | 2024-05-13 |
| DOP2024000076A (es) | 2024-06-16 |
| US20230279094A1 (en) | 2023-09-07 |
| IL312380A (en) | 2024-06-01 |
| JP2025063187A (ja) | 2025-04-15 |
| EP4423127A1 (en) | 2024-09-04 |
| AU2022376940A1 (en) | 2024-05-02 |
| JP7622019B2 (ja) | 2025-01-27 |
| CA3236555A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22084245A (es) | Compuestos y métodos dirigidos a interleucina-34 | |
| CO2020014575A2 (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| CO2022013274A2 (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
| CL2019003049A1 (es) | Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats. | |
| UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
| CO2019007830A2 (es) | Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| MX376212B (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo. | |
| CO6670589A2 (es) | Compuestos para reducir la producción de beta-amiloide | |
| DOP2021000229A (es) | Materiales y métodos para modular la inmunidad mediada por cédula t | |
| UY39011A (es) | Métodos para purificar cannabinoides, composiciones y kits de estos | |
| CL2023002966A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| GT200400076A (es) | Ligandos de receptores de cannabinoides y sus usos | |
| UY37378A (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus | |
| PA8601001A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
| BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
| CO6640211A2 (es) | Composiciones del péptido a-beta y métodos | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| ECSP24032906A (es) | Compuestos y métodos dirigidos a la interleucina-34 | |
| AR132340A1 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. |